Atorvastatin in stroke: a review of SPARCL and subgroup analysis

References

• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med1998339134913579841303
   PubMed Web of Science ®Google Scholar
• PlehnJFDavisBRSacksFMReduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) studyCirculation1999992162239892586
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• Heart Protection Collaborative Study GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• AmarencoPLabreucheJLavalléePTouboulPJStatins in stroke prevention and carotid atherosclerosis: systematic review and metaanalysisStroke2004352902290915514180
   PubMed Web of Science ®Google Scholar
• The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) InvestigatorsHigh-dose atorvastatin after stroke or transient ischemic attackN Engl J Med200635554955916899775
   PubMed Web of Science ®Google Scholar
• LiaoJKEffects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterolAm J Cardiol200596Suppl24F33F
   PubMedGoogle Scholar
• ZhangLZhangZGLiuXSHozeska-SolgotAChoppMThe PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the ratArterioscler Thromb Vasc Bio2007272470247517717296
   PubMed Web of Science ®Google Scholar
• ChenJLZhangZGLiYStatins induce angiogenesis, neurogenesis, and synaptogenesis after strokeAnn Neurol20035374375112783420
   PubMed Web of Science ®Google Scholar
• KawashimaSYamashitaTMiwaYHMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive ratsStroke20033415716312511768
   PubMed Web of Science ®Google Scholar
• LuDQuCGoussevAStatins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injuryJ Neurotrauma2007241132114617610353
   PubMed Web of Science ®Google Scholar
• BoselJGandorFHarmsCNeuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neuronesJ Neurochem2005921386139815748157
   PubMed Web of Science ®Google Scholar
• LaufsUGertzKHuangPAtorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic miceStroke2000312442244911022078
   PubMed Web of Science ®Google Scholar
• SandercockPGubitzGFoleyPCounsellCAntiplatelet therapy for acute ischaemic strokeCochrane Database Syst Rev20032CD00002912804384
   PubMedGoogle Scholar
• IsoHJacobsDRJWentworthDNeatonJDCohenJDSerum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trialN Engl J Med19893209049102619783
   PubMed Web of Science ®Google Scholar
• YanoKReedDMMacLeanCJSerum cholesterol and hemorrhagic stroke in the Honolulu heart programStroke198920146014652815179
   PubMed Web of Science ®Google Scholar
• EbrahimSSungJSongYMFerrerRLLawlorDADavey SmithGSerum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort studyBMJ2006333222816757495
   PubMed Web of Science ®Google Scholar
• LeppalaJMVirtamoJFogelholmRAlbanesDHeinonenOPDifferent risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidantsStroke1999302535254010582974
   PubMed Web of Science ®Google Scholar
• GoldsteinLBAmarencoPSzarekMon behalf of the SPARCL InvestigatorsHemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels studyNeurology702364237018077795
   PubMed Web of Science ®Google Scholar
• AmarencoPGoldsteinLBSzarekMSPARCL InvestigatorsEffects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) TrialStroke2007383198320417962589
   PubMed Web of Science ®Google Scholar
• AmarencoPGoldsteinLBCallahanA3rdSPARCL InvestigatorsBaseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialAtherosclerosis200920451552018962621
   PubMed Web of Science ®Google Scholar
• AmarencoPGoldsteinLBMessigMSPARCL InvestigatorsRelative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trialStroke2009402486249219461031
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• RothwellPMCoullAJSilverLEPopulation-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study)Lancet20053661773178316298214
   PubMed Web of Science ®Google Scholar
• JemalAWardEHaoYThunMTrends in the leading causes of death in the United States, 1970–2002JAMA20052941255125916160134
   PubMed Web of Science ®Google Scholar
• SeverPADahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trialLancet20023601623163012457784
   PubMed Web of Science ®Google Scholar
• LewisSJMoyeLASacksFMEffect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average rangeAnn Intern Med19981296816899841599
   PubMed Web of Science ®Google Scholar
• KoDTMamdaniMAlterDALipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradoxJAMA20042911864187015100205
   PubMed Web of Science ®Google Scholar
• BennerJSGlynnRJMogunHNeumannPJWeinsteinMCAvornJLong-term persistence in use of statin therapy in elderly patientsJAMA200228845546112132975
   PubMed Web of Science ®Google Scholar
• ChaturvediSZivinJABreaznaAfor the SPARCL investigatorsEffect of atorvastatin in elderly patients with a recent stroke or transient ischemic attackNeurology20097268869418768917
   PubMed Web of Science ®Google Scholar
• GoldsteinLBAmarencoPLaMonteMRelative effects of statin therapy on stroke and cardiovascular events in men and women: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) StudyStroke2008392444244818617654
   PubMed Web of Science ®Google Scholar
• AmarencoPBenaventeOGoldsteinLBResults of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypesStroke2009401405140919228842
   PubMed Web of Science ®Google Scholar
• SillesenHAmarencoPHennericiMGStroke Prevention by Aggressive Reduction in Cholesterol Levels InvestigatorsAtorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialStroke2008393297330218845807
   PubMed Web of Science ®Google Scholar
• Executive Committee for the Asymptomatic Carotid Atherosclerosis StudyEndarterectomy for asymptomatic carotid stenosisJAMA1995273142114287723155
   PubMed Web of Science ®Google Scholar
• HallidayAMansfieldAMarroJMRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative GroupPrevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trialLancet20043631491150215135594
   PubMed Web of Science ®Google Scholar
• GoldsteinLBAmarencoPZivinJStatin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) TrialStroke2009403526353119745172
   PubMed Web of Science ®Google Scholar
• MoonisMKaneKSchwiderskiUSandageBWFisherMHMG-CoA reductase inhibitors improve acute ischemic stroke outcomeStroke2005361298130015879346
   PubMed Web of Science ®Google Scholar
• ElkindMSFlintACSciaccaRRSaccoRLLipid-lowering agent use at ischemic stroke onset is associated with decreased mortalityNeurology20056525325816043795
   PubMed Web of Science ®Google Scholar
• AslanyanSWeirCJMcInnesGTReidJLWaltersMRLeesKRStatin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control studyEur J Neurol20051249349815958087
   PubMed Web of Science ®Google Scholar
• ReevesMJGarganoJWLuoZMullardAJJacobsBSMajidAEffect of pretreatment with statins on ischemic stroke outcomesStroke2008391779178518369173
   PubMed Web of Science ®Google Scholar
• KarkiKKnightRAHanYSimvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhageStroke2009403384338919644071
   PubMed Web of Science ®Google Scholar
• LapchakPAHanMKThe 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbitsBrain Res200915130314415019781532
   PubMedGoogle Scholar
• FitzMauriceEWendellLSniderREffect of statins on intracerebral hemorrhage outcome and recurrenceStroke2008392151215418436876
   PubMedGoogle Scholar
• LekerRRKhourySTRafaeliGShwartzREichelRTanneDNASIS InvestigatorsPrior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS)Stroke2009402581258419407227
   PubMed Web of Science ®Google Scholar
• AmarencoPGoldsteinLBSillesenHStroke Prevention by Aggressive Reduction in Cholesterol Levels InvestigatorsCoronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialStroke20104142643020110538
   PubMed Web of Science ®Google Scholar
• FitchettDHGoodmanSGLangerAIschemic stroke: A cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialCan J Cardiol20082470570818787721
   PubMed Web of Science ®Google Scholar
• AmarencoPStegPGStroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke preventionEur Heart J2008291605160718523057
   PubMed Web of Science ®Google Scholar